REPLIMUNE GROUP INC (REPL)       24.06  +0.97 (+4.2%)

24.06  +0.97 (+4.2%)

US76029N1063 - Common Stock - Premarket: 24.9768 +0.92 (+3.81%)


Fundamental Rating

3

Overall REPL gets a fundamental rating of 3 out of 10. We evaluated REPL against 637 industry peers in the Biotechnology industry. REPL has a great financial health rating, but its profitability evaluates not so good. REPL has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

1

REPL has a Return On Assets of -33.65%. This is better than the industry average of -44.55%.
The profitability ratios for REPL are negative, so there is not much use analyzing them.

REPL has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for REPL.
VS Industry

ROA (-33.65%) VS Industry: 66% outperformed.

-3,944.82
115.38

Valuation

Valuation Rating

1

When comparing the current price to the book value of REPL, we can conclude it is valued correctly. It is trading at 3.12 times its book value.
The Price/Earnings Ratio is negative for REPL. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REPL. No positive earnings are expected for the next year.
Compared to an average industry price book ratio of 1.69, REPL is valued more expensive than its industry peers.
VS Industry

Price/Book (3.12) VS Industry: 26% outperformed.

138.37
0.09

Growth

Growth Rating

0

REPL is expected to show a decrease in Earnings Per Share. In the coming 5 years, the EPS will decrease by -6.42% yearly.

REPL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.71%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -42.71% -42.02% -26.87% -11.21% -6.42%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

8

A Current Ratio of 16.12 indicates that REPL has no problem at all paying its short term obligations.
The Current Ratio of REPL is much better than the industry average of 6.11. REPL has a better rating than 86% of its industry peers.
A Quick Ratio of 16.12 indicates that REPL has no problem at all paying its short term obligations.
The Quick Ratio of REPL is much better than the industry average of 6.02. REPL has a better rating than 87% of its industry peers.

REPL has an Altman-Z score of 12.42. This indicates that REPL is financially healthy and little risk of bankruptcy at the moment.
REPL has one of the better Altman-Z scores in its industry. It is much better than the industry average of -0.65. REPL has a better score than 90% of its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.00, REPL is more dependent on financing than its industry peers.
Although this is true, REPL has a very low Debt to Equity (0.06). So we won't put much weight on the industry comparison.
The Piotroski-F score of REPL is 2.00. This is a very weak score and indicates problems in health and profitability for REPL.
VS Industry

Debt/Equity (0.06) VS Industry: 26% outperformed.

15.37
0.00

Quick Ratio (16.12) VS Industry: 87% outperformed.

0.02
84.53

Current Ratio (16.12) VS Industry: 86% outperformed.

0.02
85.09

Altman-Z (12.42) VS Industry: 90% outperformed.

-1,822.17
440.11

Dividend

Dividend Rating

0

REPL does not give a dividend.

REPL Daily chart

REPLIMUNE GROUP INC24.06

NASDAQ:REPL (12/8/2022, 7:04:32 PM)+0.97 (+4.2%)

Premarket: 24.9768 +0.92 (+3.81%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-03 2022-11-03/bmo Earnings (Next) 02-01 2023-02-01
Ins Owners 18.52% Inst Owners 82.96%
Market Cap 1.20B Analysts 86.25
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 3.12
EV/EBITDA N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -42.71% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -41.07%
EPS Next Y -42.02% EPS Next 2Y -26.87%
EPS Next 3Y -11.21% EPS Next 5Y -6.42%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 16.12 Quick Ratio 16.12
Altman-Z 12.42 F-Score 2
Debt/Equity 0.06 WACC N/A
ROIC/WACC N/A
Profitability
ROA -33.65% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA